ArticleGut2007
High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease.
Article in Gut, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 196 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
196 citing papers in PubMed, 2 syntheses or guidelines pooled it, 426 citations in OpenAlex.
- Searching for a Consensus Among Inflammatory Bowel Disease Studies: A Systematic Meta-Analysis.Inflammatory bowel diseases · 2023Pooled it
- Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences.United European gastroenterology journal · 2019Pooled it
- A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis.Gastroenterology · 2021Trial
- Trial
- Protease-serpin-microbiome interactions in inflammatory bowel disease: toward integrated biomarkers of gut health.Gut microbes · 2026Review
- A Comprehensive Review of IL-10 and IL-10 Receptor Deficiencies: From Basic Science to Clinical Bedside.Clinical reviews in allergy & immunology · 2026Review
- Genotoxic Bacteria and Oncogenic Viruses in Colorectal Cancer: Evidence, Gaps, and a Proposed Interaction Model.International journal of molecular sciences · 2026Review
- Article
- Intestinal epithelial PTPN2 limits pathobiont colonization by immune-directed antimicrobial responses.Gut microbes · 2025Article
- Collective dynamics ofmBio · 2025Article
- Anti-inflammatory effects and gut microbiota modulation of synbiotic mulberry in DSS-induced colitis rats.Molecular and cellular biochemistry · 2025Article
- UropathogenicInternational journal of molecular sciences · 2025Article
- Host-pathobiont interactions in Crohn's disease.Nature reviews. Gastroenterology & hepatology · 2025Review
- The Therapeutic Potential of Gut-Microbiota-Derived Metabolite 4-Phenylbutyric Acid inInternational journal of molecular sciences · 2025Article
- Novel strategies for modulating the gut microbiome for cancer therapy.Advanced drug delivery reviews · 2024Review
- CViewer: a Java-based statistical framework for integration of shotgun metagenomics with other omics datasets.Microbiome · 2024Article
- The development of probiotics and prebiotics therapy to ulcerative colitis: a therapy that has gained considerable momentum.Cell communication and signaling : CCS · 2024Review
- Cataloging the phylogenetic diversity of human bladder bacterial isolates.Genome biology · 2024Article
- Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions.eGastroenterology · 2024Review
- The distinct transcriptome of virulence-associated phylogenetic group B2Microbiology spectrum · 2023Article
136 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt is not clear which species of bacteria may be involved in inflammatory bowel disease (IBD). One way of determining which bacteria might be likely candidates is to use culture-independent methods to identify microorganisms that are present in diseased tissues but not in controls.
aims(1) To assess the diversity of microbial communities of biopsy tissue using culture-independent methods; (2) to culture the bacteria found in the tissues of patients with IBD but not in the controls; (3) to identify potential virulence factors associated with cultured bacteria.
methods84 biopsy specimens were collected from 15 controls, 13 patients with Crohn's disease (CD) and 19 patients with ulcerative colitis (UC) from a population-based case-control study. Ribosomal intergenic spacer analysis (RISA) was conducted to identify unique DNA bands in tissues from patients with CD and UC that did not appear in controls.
resultsRISA followed by DNA sequencing identified unique bands in biopsy specimens from patients with IBD that were classified as Escherichia coli. Targeted culture showed a significantly (p<0.05) higher number of Enterobacteriaceae in specimens from patients with IBD. The B2+D phylogenetic group, serine protease autotransporters (SPATE) and adherence factors were more likely to be associated with tissues from patients with UC and CD than with controls.
conclusionsThe abundance of Enterobacteriaceae is 3-4 logs higher in tissues of patients with IBD and the B2+D phylogenetic groups are more prevalent in patients with UC and CD. The B2+D phylogenetic groups are associated with SPATE and adherence factors and may have a significant role in disease aetiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.